NCT05461170Phase 2Active not recruiting

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Study sponsor: Vir Biotechnology, Inc. · VIR

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2031-11Estimated

Enrollment · participants95Actual

Source updated2026-06-26Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-26 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2029-08

+ Updated value

2031-11

Check registry source

Study details

Conditions studied

Hepatitis D, Chronic

Treatments or interventions studied

VIR-2218DrugAlso known as Elebsiran
VIR-3434DrugAlso known as Tobevibart
NRTIDrug

Primary outcomes · main study measures

measure: Proportion of participants with undetectable HDV RNA (< limit of detection [LOD]) or ≥ 2 log10 decrease in HDV RNA from baseline and alanine aminotransferase (ALT) normalization (ALT < upper limit of normal [ULN]) at Week 24; timeFrame: Up to 24 Weeks; measure: Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); timeFrame: Up to 360 Weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history